Effect of nalbuphine on prevention of Catheter-Related Bladder Discomfort after gynecological laparoscopic surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500102866

Enrollment

Unknown

Registered

2025-05-21

Start date

2025-06-01

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Catheter-related bladder discomfort, CRBD

Interventions

Nalbuphine Group(Group N):30min before the end of surgery, 0.2mg/kg nalbuphine was diluted to 10ml with normal saline and slowly injected intravenously.

Control Group(Group C):30min before the end of surgery, 10ml of normal saline was slowly injected intravenously

Eligibility

Sex/Gender

Female

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Women undergoing gynecological surgery aged 18-60 years 2. ASA I-II 3. Elective gynecologic laparoscopy or combined hysteroscopy and laparoscopy surgery.

Exclusion criteria

Exclusion criteria: 1.Drug contraindications, allergies 2.Drug abuse history 3. A history of significant neurological symptoms such as dizziness, headache, and blurred vision 4. Patients with asthma, chronic obstructive pulmonary disease, and severe apnea syndrome 5. Patients undergoing laparoscopic surgery during pregnancy or lactation 6. Patients who refuse to participate

Design outcomes

Primary

Measure	Time frame
Incidence of CRBD;	—

Secondary

Measure	Time frame
Adverse events;VAS score;Ramsay score;	—

Countries

China

Contacts

Public ContactRouxuan Zhou

Shenzhen Maternity and Child Healthcare Hospital

zhourouxuan@126.com+86 139 2746 5758

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026